Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Medicolegal and insurance issues regarding BRCA1 and BRCA2 gene tests in high income countries.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 3 Jun 2024

Oliva Riccardo, Grassi Simone, Marchetti Claudia, Cazzato Francesca, Marinelli Roberta, Scambia Giovanni, Fagotti Anna

Abstract excerpt

Hereditary breast and ovarian cancer syndrome is an autosomal dominant cancer susceptibility syndrome mainly due to variants in BRCA1 or BRCA2 genes. Patients presenting with BRCA1 or BRCA2 gene mutations have a lifetime risk of developing breast or ovarian cancer (80% and 40%, respectively). Genetic testing to explore the predisposition to develop cancer represents a pivotal factor in such cases, and this review...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Genes, BRCA1

Share to Genes, BRCA2

Share to Genetic Counseling

Share to Insurance, Health

Share to Ovarian Neoplasms

Source

Identifiers

PMID: 38642925
DOI: 10.1136/ijgc-2023-005225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Medicolegal and insurance issues regarding BRCA1 and BRCA2 gene tests in high income countries.PMID 38642925Read ↗

BRCA1/2 testing for genetic susceptibility to cancer after 25 years: A scoping review and a primer on ethical implications.Semantic proximity Read ↗

BRCA1 and BRCA2 gene mutations: decision-making dilemmas concerning testing and management.Semantic proximity Read ↗

[Genetic predisposition to breast and ovarian cancer: importance of test results].Semantic proximity Read ↗

Genetic Testing: Disclosure to Patients and Payors and the Risks In Between.Semantic proximity Read ↗

When, how and why BRCA1 and BRCA2 genetic testing is offered to patients who do not meet standard criteriaSemantic proximity Read ↗

[Entitlement to prophylactic treatment in cases of genetic predisposition for breast cancer : Interdisciplinary perspectives].Semantic proximity Read ↗

Social and ethical implications of BRCA testing.Semantic proximity Read ↗

Points to consider to avoid unfair discrimination and the misuse of genetic information: A statement of the American College of Medical Genetics and Genomics (ACMG)Semantic proximity Read ↗

Disclosure of genetic tests for health insurance: is it ethical not to?Semantic proximity Read ↗

BRCA 1/2 gene mutation testing-based cancer prevention and the moral concerns of different types of patients.Semantic proximity Read ↗

Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.Semantic proximity Read ↗

Genetic testing and insurance. The Ad Hoc Committee on Genetic Testing/Insurance Issues.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.